Navigation Links
Onyx Pharmaceuticals Presents Carfilzomib Data at 53rd American Society of Hematology Annual Meeting
Date:12/12/2011

Oncology Division, Bone Marrow Transplantation & Leukemia Section at the Washington University School of Medicine, who presented the data. "The efficacy and safety results from this study suggest that carfilzomib has the potential to be used in earlier lines of treatment in patients with multiple myeloma."

Patients were divided into two cohorts. In Cohort 1 (n=59), patients received 20mg/m(2) for all treatment cycles.  In Cohort 2 (n=67), patients received a dose-escalating regimen of 20mg/m(2) for the first cycle and 27mg/m(2) for all remaining treatment cycles.

The 59 evaluable patients who received carfilzomib at 20mg/m(2) achieved an ORR of 42 percent and a CBR of 59 percent. This cohort demonstrated a TTP of 8.3 months and a DOR of 13.1 months. The median overall survival (OS) has not yet been reached.  Sixty-six percent of these patients were refractory to their most recent therapy prior to entering the trial.

No new or unexpected adverse events were observed. The most common Grade 3 treatment-emergent adverse events included: anemia (Cohort 1, 12 percent; Cohort 2, 17 percent); thrombocytopenia (Cohort 1, 15 percent; Cohort 2, 11 percent); neutropenia (Cohort 1, 12 percent; Cohort 2, 14 percent); lymphopenia (Cohort 1, 14 percent; Cohort 2, 19 percent); and pneumonia (Cohort 1, 14 percent; Cohort2, 11 percent). Peripheral neuropathy of any grade was infrequent.

"This trial highlights our commitment to understanding carfilzomib across treatment settings," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals. "Efficacy and safety data from this trial was included as part of the New Drug Application (NDA) for carfilzomib that was recently accepted by the U.S. Food and Drug Administration (FDA) under the accelerated approval process for the treatment of patients with relapsed and refractory multiple myeloma."

Abstract #2930:
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... and RALEIGH, N.C. , ... of Endo International plc (NASDAQ: ENDP ) ... BDSI ) announced today that they have submitted ... Film to the U.S. Food and Drug Administration (FDA).  ... management of pain severe enough to require daily, around-the-clock, ...
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has ... Glucose Market" report to their offering. ... insight focuses on the developments in the self-monitoring blood ... . Reimbursement analysis and the effects of competitive bidding ... 73 SMBG meters have been performed, based on the ...
(Date:12/22/2014)... STOCKHOLM , Dec. 22, 2014 /PRNewswire/ ... Auxilium Pharmaceuticals, Inc. today announced that the Committee for ... Medicines Agency (EMA) has adopted a positive opinion for ... treatment of adult men with Peyronie,s disease with a ... degrees at the start of therapy. The ...
Breaking Medicine Technology:Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5US Self-monitoring Blood Glucose Market 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
(Date:12/25/2014)... 2014 Recently, LunaDress.co.uk has updated its blog to ... accessories. Now, all of the models at LunaDress.co.uk come with big ... lifts the wedding veil can turn out to be a most ... wedding veil can always bring surprise to a wedding. On the ... to choose veils for a big day . , Going ...
(Date:12/25/2014)... 25, 2014 (HealthDay News) -- The risk of burns ... so you need to be extra cautious, an expert ... see a significant increase in patients coming in with ... Suffolk County Volunteer Firefighters Burn Center of Stony Brook ... be full of joy, but if not careful, could ...
(Date:12/25/2014)... 24, 2014 (HealthDay News) -- Among early stage breast ... than half of one percent will eventually develop leukemia ... reveals. The finding comes from a review of ... and 2007, and it suggests that the risk for ... experts had previously thought. "The frequency of bone ...
(Date:12/25/2014)... December 25, 2014 AngelWeddingDress.com tries its ... the online realm. Today, the business has introduced its ... site-wide prom dress promotion. , The new prom outfits ... and every dress lover. They are specially designed for ... prom dresses should visit its website before Jan. ...
(Date:12/25/2014)... SmileStix ” was featured on NewsWatch as part of its ... on the iOS, Android, and Windows markets. Andrew Tropeano, a ... review and shared with viewers how this is an application ... goes, “A picture says a thousand words.” It’s true. There ... image, because each picture holds a unique and special meaning. ...
Breaking Medicine News(10 mins):Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... operated on, or the wrong transplant, study found , , TUESDAY, ... in eye surgery, say U.S. researchers who analyzed 106 cases ... the wrong site or using wrong procedure. , The ... College in New York found: , The most common ...
... Addressing Health Disparities, NASHVILLE, Tenn., Nov. 13 ... grant to the Meharry Medical,College Center for Women,s ... study of health disparities among women of color. ... advance the Center,s work in,addressing diseases that disproportionately ...
... Influenza and Pneumococcal Alert Coalition (CIPAC) and RediClinic, offers Denver, ... help protect themselves and the many ... Center at Aurora during ... this special time of year, - Last year, the 2006-2007 ...
... physician evaluations will have,national impact, NEW YORK, ... Nancy H. Nielsen, M.D., Ph.D., AMA President-elect:, ... New York Attorney General Cuomo has expanded health ... month on,physician ranking programs. Aetna,s decision to join ...
... (PHILADELPHIA) Inappropriate activation of a single enzyme, telomerase, ... in as many as 90 percent of all of ... identified in human tumors, scientists have eyed the enzyme ... drugs. , Now, researchers working at The Wistar ...
... from Wake Forest University Baptist Medical Center suggests that ... kidney transplant and that using donated kidneys that ... burgeoning organ shortage among older adults. , In the ... barrier for both organ donation and transplantation, said Phillip ...
Cached Medicine News:Health News:Eye Surgery Errors Rare But Serious 2Health News:Wal-Mart Foundation Announces $1 Million Grant to the Meharry Medical College Center for Women's Health Research 2Health News:Wal-Mart Foundation Announces $1 Million Grant to the Meharry Medical College Center for Women's Health Research 3Health News:Wal-Mart Foundation Announces $1 Million Grant to the Meharry Medical College Center for Women's Health Research 4Health News:Colorado Influenza and Pneumococcal Alert Coalition (CIPAC) Partners with Novartis Vaccines for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 2Health News:Colorado Influenza and Pneumococcal Alert Coalition (CIPAC) Partners with Novartis Vaccines for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 3Health News:Colorado Influenza and Pneumococcal Alert Coalition (CIPAC) Partners with Novartis Vaccines for Holiday Vaccination Clinic, Making Influenza Vaccination Convenient for Shoppers 4Health News:AMA Commends Aetna for Quality First Commitment 2Health News:Telomerase enzyme structure provides significant new target for anti-cancer therapies 2Health News:Telomerase enzyme structure provides significant new target for anti-cancer therapies 3Health News:Higher-risk kidneys may help solve organ shortage facing older adults 2Health News:Higher-risk kidneys may help solve organ shortage facing older adults 3
System, English (Continental cord), 230 VAC....
Portable mini halogen light....
Micro-mini fiber optic light....
Miniature high intensity fiber optic light. The ultra-thin fiber-optic cable is smaller and lighter than a standard electrical cord....
Medicine Products: